Secondary lymphedema

ImpediMed Reaches Milestone of 500,000 Patient Tests Performed with the SOZO Digital Health Platform

Retrieved on: 
Wednesday, November 2, 2022

CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD) reached a milestone of 500,000 patient tests performed with the SOZO Digital Health Platform.

Key Points: 
  • CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD) reached a milestone of 500,000 patient tests performed with the SOZO Digital Health Platform.
  • With over 1,100 devices in use globally, the pace of patient testing has accelerated with 100,000 patient tests performed in just the past six months.
  • "Reaching 500,000 patient tests is an important milestone and positive indicator of the future health of our business.
  • The SOZO Digital Health Platform launched in 2017 and improvements delivered with four generations of software advancements have led to increased adoption and utilization every year.

Tactile Medical Announces Publication of Expert Opinion Consensus Statement in Phlebology Recommending the Use of Pneumatic Compression for Lymphedema

Retrieved on: 
Tuesday, June 7, 2022

MINNEAPOLIS, June 07, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the publication of an expert opinion consensus statement.

Key Points: 
  • MINNEAPOLIS, June 07, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the publication of an expert opinion consensus statement.
  • Three independent societies consensus endorsements were published in peer-reviewed Phlebology: The Journal of Venous Disease.
  • The statement affirmed that pneumatic compression should be recommended as a treatment for lymphedema, including lymphedema which is secondary to chronic venous insufficiency (CVI).
  • 92% of the panel agreed that sequential pneumatic compression should be recommended for lymphedema patients.

Global Lymphedema Treatment Market (2022 to 2030) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022

The increasing number of individuals being affected by Lymphedema is anticipated to drive the growth of the Lymphedema cure industry.

Key Points: 
  • The increasing number of individuals being affected by Lymphedema is anticipated to drive the growth of the Lymphedema cure industry.
  • Furthermore, the increasing healthcare expenditure coupled with the growing innovation across the healthcare sector is further projected to drive the industry growth.
  • In addition, the launch of new medical devices by pharmaceutical companies is also fueling industry growth across the globe.
  • Based on the type, the secondary Lymphedema segment is dominating the global industry and is anticipated to lead the industry over the forecasting period.

Global Lymphedema Treatment Market Forecast (2021 to 2028) - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, February 28, 2022

The "Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Condition Type, Treatment Type, and End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Condition Type, Treatment Type, and End-User" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the lymphedema treatment market is attributed to the escalating incidence of secondary lymphedema, and the increasing number of healthcare services and lymphedema management programs.
  • Based on condition type, the global lymphedema treatment market has been segmented into primary lymphedema and secondary lymphedema.
  • Based on treatment type, the global lymphedema treatment market has been segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others.

New Data Evaluating ImpediMed's SOZO® Digital Health Platform to Assess Bone in Cancer Patients to be Presented at 39th Annual Miami Breast Cancer Conference

Retrieved on: 
Tuesday, February 15, 2022

The Miami Breast Cancer Conference draws the multidisciplinary cancer care team for in-depth discussion about current topics and technologies for breast cancer care.

Key Points: 
  • The Miami Breast Cancer Conference draws the multidisciplinary cancer care team for in-depth discussion about current topics and technologies for breast cancer care.
  • "The Miami Breast Cancer Conference is run by leaders in breast cancer care from every oncology specialty," commented Richard Carreon, Managing Director and CEO of ImpediMed.
  • "This is the ideal venue to present the new data evaluating SOZO to assess changes in bone in cancer patients during and after treatment.
  • Expanding the use of SOZO to help care for cancer patients is central to ImpediMed's growth strategy in the oncology marketplace.

Solidea U.S. Announces Massive Price Reduction for All Active Massage and Classic Compression Garments

Retrieved on: 
Thursday, August 5, 2021

WEST HARTFORD, Conn., Aug. 5, 2021 /PRNewswire/ -- Solidea U.S. , the only authorized distributor of Italian-made compression garment manufacturer Solidea , has announced a permanent price reduction of its entire U.S. inventory of compression garments.

Key Points: 
  • WEST HARTFORD, Conn., Aug. 5, 2021 /PRNewswire/ -- Solidea U.S. , the only authorized distributor of Italian-made compression garment manufacturer Solidea , has announced a permanent price reduction of its entire U.S. inventory of compression garments.
  • These compression garments have literally changed my life, and I hope this price reduction will give more people the financial flexibility to access them, too."
  • Solidea U.S. products impacted by this price reduction include all Solidea Active Massage Compression garments (leggings, arm sleeve, abdominal band, capri, armbands, shorts, bike short, knee-high socks, gauntlet, ankle socks, calf sleeves, men's long brief, braless top, mid-calf socks, men's short brief, and the anti-embolism thigh-highs), as well as all Classic Medical Compression and Maternity Compression garments.
  • The Connecticut-based company provides state-of-the-art compression garments and is dedicated to providing help to those who must wear compression on a regular basis.

PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema

Retrieved on: 
Thursday, December 10, 2020

PureTech today announced the initiation of a Phase 2a proof-of-concept study of LYT-100 (deupirfenidone), an anti-fibrotic and anti-inflammatory agent, in patients with breast cancer-related, upper limb secondary lymphedema.

Key Points: 
  • PureTech today announced the initiation of a Phase 2a proof-of-concept study of LYT-100 (deupirfenidone), an anti-fibrotic and anti-inflammatory agent, in patients with breast cancer-related, upper limb secondary lymphedema.
  • LYT-100 has also been evaluated in preclinical lymphedema models, where it halted progression of lymphedema and reduced swelling volume.
  • The randomized, placebo-controlled, Phase 2a proof-of-concept study of LYT-100 is expected to enroll up to 50 patients with breast cancer-related, upper limb secondary lymphedema.
  • PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema.

Tactile Medical Announces New Clinical Publication Highlighting the Role of Chronic Venous Insufficiency in Causing Lower Extremity Lymphedema

Retrieved on: 
Thursday, February 13, 2020

The study, titled The clinical characteristics of lower extremity lymphedema in 440 patients, was a 3-year, single-center retrospective cohort study conducted by Steven M. Dean, DO* et al.

Key Points: 
  • The study, titled The clinical characteristics of lower extremity lymphedema in 440 patients, was a 3-year, single-center retrospective cohort study conducted by Steven M. Dean, DO* et al.
  • Despite a likely referral bias favoring the cancer population, researchers found that chronic venous insufficiency was the most common cause of lymphedema, responsible for 41.8% of lower extremity lymphedema cases, followed by cancer-related lymphedema (33.9%), primary lymphedema (12.5%) and lipedema with secondary lymphedema (11.8%).
  • Based on these findings they concluded that chronic venous insufficiency, not cancer-related therapy, may be the most common cause of lower extremity lymphedema in the U.S.
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.

PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema

Retrieved on: 
Wednesday, July 17, 2019

There are no approved drug therapies on the market that can treat lymphedema.

Key Points: 
  • There are no approved drug therapies on the market that can treat lymphedema.
  • PureTechs product candidate, LYT-100, has the potential to fulfill a widespread need for an effective approach that can treat secondary lymphedema without surgery.
  • PureTech is committed to developing a long-awaited treatment for the millions of people living with lymphedema, said Daphne Zohar, co-founder and chief executive officer of PureTech.
  • There are currently no FDA-approved therapeutics to treat lymphedema, suggesting a major need for millions of patients.

American Society of Breast Surgeons: Innovative Lymphedema Surveillance Program and Early Intervention Significantly Help Prevent Progression

Retrieved on: 
Thursday, May 2, 2019

Surveillance of women at risk for breast cancer-related lymphedema using bioimpedance spectroscopy (BIS) was more effective in preventing lymphedema progression than traditional arm circumference measurement, when each is combined with immediate compression therapy.

Key Points: 
  • Surveillance of women at risk for breast cancer-related lymphedema using bioimpedance spectroscopy (BIS) was more effective in preventing lymphedema progression than traditional arm circumference measurement, when each is combined with immediate compression therapy.
  • They were presented this week at the annual meeting of the American Society of Breast Surgeons.
  • Breast cancer-related lymphedema is a chronic, debilitating swelling of the arm that may result from surgery, radiation, or chemotherapy affecting the lymph nodes.
  • Lymphedema significantly lowers quality-of-life and consistently ranks as the number one fear of breast cancer survivors, says lead study author Sheila Ridner, PhD, RN, FAAN, Vanderbilt University School of Nursing.